Search Results 191-200 of 16975 for Antagonist

1. Polycystic Kidney Disease Clinical Trials - Mayo Clinic Research

   The vasopressin V2 receptor antagonist lixivaptan has also been shown to ameliorate polycystic disease manifestations in animal models of the disease.

2. A Study to Evaluate the Pharmacokinetics of Low-Dose Bevacuzimab in Reducing Free Plasma VEGF-A in Hemodialysis Patients - Mayo Clinic

   Treatment with vitamin K-antagonists or direct thrombin inhibitors with an INR ≥2; All patients (including both female patients of childbearing potential ...

3. Gastric Bypass Clinical Trials - Mayo Clinic Research

   The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of ...

4. A Study to Evaluate Stereotactic Radiosurgery Versus Hippocampal-Avoidant Whole Brain Radiotherapy for 10 or Fewer Brain Metastases from Small Cell Lung Cancer - Mayo Clinic

   Current use of (other NMDA antagonists) amantadine, ketamine, or dextromethorphan. Radiographic evidence of hydrocephalus or other architectural change of ...

5. Polycystic kidney disease

   Preclinical studies in drug therapies for polycystic kidney disease, such as octreotide and vasopressin antagonists. Finding effective therapies for ...

6. A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

   Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (other anticoagulants allowed). Requires treatment with proton pump ...

7. Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer - Mayo Clinic

   ... antagonists and antiandrogens) within 1 year prior to randomization, unless it was in the neoadjuvant and/or adjuvant setting; agents such as 5 alpha ...

8. A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome - Mayo Clinic

   ... antagonists, dabigatran, rivaroxaban and apixaban), or within 7 days prior to Day 1, Visit 1 has taken any antiplatelet (including but not limited to ...

9. Anticoagulant Risk Explored - Mayo Clinic News Network

   DOACs — which unlike warfarin don't require ongoing blood tests — are also known as non-Vitamin K antagonist oral anticoagulants, or NOACs. (Read more about ...

10. Study to Evaluate Chemoembolization Combined with Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma - Mayo Clinic

    Systemic anticoagulation allowed, excluding Vitamin K antagonists. History of arterial thrombotic event, including myocardial infarction, unstable angina ...